QT Ultrasound Partners with Shanghai-Based TCL Healthcare Equipment

September 10, 2020

QT Ultrasound, developer of the QTscan®, will bring its radiation- and compression-free 3D breast imaging technology to China, and other Asian markets, through a partnership with TCL Healthcare Equipment. The Shanghai-based company focuses on medical imaging equipment with proven expertise in bringing innovative products to Asia.

QT Ultrasound focused on China for international expansion because China is the second-largest medical device market in the world, following the United States. The market will continue to grow because the Chinese government is focused on improving healthcare access and outcomes by embracing technological innovation. The QTscan is particularly advantageous for Asian women because of its ability to accurately image dense breasts; an estimated 70% of Asian women have dense breasts, for which mammography has proven to be less sensitive in identifying masses. Both companies believe China is a country where the QTscan can have a very positive impact on women’s healthcare.

“QT Ultrasound is excited to partner with TCL Healthcare to bring our safe, innovative breast imaging technology to China. This team has the knowledge, experience, and relationships to take the QT Ultrasound Breast Scanner from approval through commercialization. We could not have found better partners,” says QT Ultrasound’s CEO and Founder, Dr. John Klock.

Mr. George Chan, Chairman of TCL Healthcare, understands that for health care to help save more lives, it needs to be affordable, which became the company’s mission. Mr. Chan says, “The QT Ultrasound Breast Scanner is exactly the right technology at the right time and will further our goal of screening for common cancers, especially screening for women – quickly, safely, and affordably.”

QT Ultrasound and TCL Healthcare share ambitious goals for providing women across Asia access to the QTscan. They expect to quickly commercialize the QTscan in China’s healthcare institutions and become a leader in the rapidly growing, breast imaging arena.

 

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”
Exit mobile version